Background
==========

There is an increasing incidence of metabolic syndrome (MS) which is characterized by abdominal obesity, hypertriglyceridemia, low serum high density lipoprotein cholesterol, elevated blood pressure, and elevated fasting plasma glucose \[[@B1]\]. The metabolic syndrome can cause or intensify cardiovascular, as well as renal disease \[[@B1],[@B2]\]. One of the possible etiologies of the metabolic syndrome is insulin resistance associated with hyperinsulinemia \[[@B1]-[@B4]\]. The stimulatory effect of insulin on sympathetic drive \[[@B5]\], vascular smooth muscle growth \[[@B6]\] and sodium and water retention \[[@B7]\] and its inhibitory effect on prostacyclin synthesis \[[@B8]\] have been suggested to be involved in the pathogenesis of obesity-related hypertension.

Dopamine, a well recognized neurotransmitter in the central nervous system, is also an important modulator of renal and adrenal function, sodium balance, and blood pressure. Dopamine receptors are classified into two subfamilies: the D~1~-like receptor subfamily includes the D~1~ and the D~5~ receptors, while the D~2~, D~3~ and D~4~ receptors belong to the D~2~-like receptor subfamily. Dysfunction of the renal dopaminergic system is implicated in the pathogenesis and/or maintenance of hypertension \[[@B9],[@B10]\].

The obese Zucker rat is a model of metabolic syndrome characterized by hyperinsulinemia, hyperglycemia, and hypertension. Dopamine has been implicated in the development of obesity, caused, in part, by increased food intake due to decreased dopaminergic function, specifically the D~2~ receptor, in the central nervous system \[[@B11],[@B12]\]. D~1~ receptor mediated-natriuresis and diuresis are also impaired in obese Zucker rats \[[@B13],[@B14]\]. Although the kidney is important in the long-term regulation of blood pressure \[[@B15]\], hypertension is also accompanied by increased vascular resistance \[[@B16]\]. Dopamine receptors are expressed in resistance vessels. In the rat mesenteric artery, D~1~ and D~5~ receptors are expressed in the tunica media while D~2~-like receptors are expressed mainly at the adventitia-tunica media transitional zone. The increase in blood pressure with aging has been related to a decrease in the expression of arterial D~1~, D~2~, and D~5~ receptor \[[@B17]\]. However, the role of the arterial D~1~ receptor in the hypertension of obese Zucker rats is not clear. Our current study tested the hypothesis that the vasorelaxant effect of the D~1~ receptor is impaired in obese Zucker rats.

Methods
=======

Animal experiments
------------------

Male obese Zucker rats and age-matched male lean Zucker rats were housed in plastic cages and fed normal rodent chow and tap water. Twelve obese Zucker rats (six to eight-weeks old) were randomly divided into two groups: 1) one group consisted of obese rats treated (6 weeks) with oral rosiglitazone maleate (10 mg/kg, suspended in 1% carboxy methyl cellulose in distilled water); and 2) the other group consisted of obese control rats treated with the vehicle (1% carboxy methyl cellulose). Eighteen lean Zucker rats (eight to ten-weeks old) were randomly divided into three groups: 1) control rats fed normal diet and treated with vehicle; 2) rats fed control diet and treated with STZ (single intraperitoneal injection, 65 mg/kg); and 3) rats fed high-fat diet (with 50% fat-derived calories) for one month.

All experiments were approved by the Daping Hospital Animal Use and Care Committee and all procedures were approved by the Experimental Animals Committee of Daping Hospital.

Blood pressure and plasma glucose and insulin measurements
----------------------------------------------------------

After an overnight fast, obese and lean Zucker rats were anesthetized with pentobarbital (Nembutal) with an initial dose of 60 mg/kg, followed by constant infusion at 40 mg/kg/hr \[[@B18]\]. Following a tracheotomy, the left carotid artery was catheterized with polyethylene-50 tubing for blood pressure monitoring. Blood pressure and heart rate were allowed to stabilize for 10 minutes \[[@B19]\] before accepting the blood pressure and heart rate observed as baseline. The abdomen was opened to expose the abdominal aorta and blood samples were collected from the aorta in EDTA-coated tubes for measurement of plasma glucose and insulin, and then the rats were sacrificed by an overdose of pentobarbital (100 mg/kg body wt). Plasma glucose concentrations were determined by using Accu-Chek Advantage glucose monitoring system. Plasma insulin levels were measured by a rat insulin 96-well plate assay (Millipore Co., St Charles, MO).

Preparation and study of small resistance arteries
--------------------------------------------------

Each rat was anesthetized with sodium pentobarbital (60 mg/kg). The entire mesenteric bed was removed carefully and placed in ice-cold physiological salt solution (PSS) containing (mM):NaCl 119, KCl 4.7, CaCl~2~·H~2~O 2.5, MgSO4·H~2~O 1.17, NaH~2~CO~3~ 25, KH~2~PO~4~ 1.18, EDTA 0.027, and glucose 5.5, adjusted to pH 7.4. The mesenteric artery was carefully and quickly dissected from the surrounding fat and connective tissues. Third-order branches of the superior mesenteric artery (resting arterial diameter: 200 ± 20 μm) were cut into rings approximately 2 mm in length, and mounted on 40 μm stainless-steel wires in an isometric Mulvany-Halpern small-vessel myograph (model 91 M610, J.P. Trading, Science Park, Aarhus, Denmark) \[[@B20]\]. One wire was attached to a force transducer and the other to a micrometer so that wall tension can be measured at a predetermined internal diameter. The rings were maintained in PSS at 37°C and continuously bubbled with oxygen (95%) and carbon dioxide (5%) (Carbogen) \[[@B21]\]. The dissecting procedures were performed with extreme care to protect the endothelium from inadvertent damage, proved by a normal response to acetylcholine (Ach) (10^-5^ Ach-induced relaxation \>80% of basal values of arteries preconstricted with phenylephrine HCl \[PHE, 10^-5^M\]). In some vessels, the endothelium was removed by pulling a hair along the inside of the vessel; successful denudation of the endothelium was confirmed by the absence of relaxation with Ach (10^-5^M) \[[@B22]\]. Following mounting, the arterial ring was equilibrated in PSS for 1 hr at 37°C at a wall tension of 0.1 mN/mm. Based on preliminary data from \>100 vessels, we confirmed that a normalized circumference (L~0~) = 0.9 L100 resulted in maximal active force development. The vessels were studied at L~0~ in all subsequent protocols. After determining the response to Ach, as indicated above, the vessels were rinsed three times with fresh PSS and allowed to recover to baseline for 15 minutes. In the first set of experiments, the rings were contracted with phenylephrine HCl (10^-5^M) and high-potassium PSS (KPSS, 125 mM) to obtain the maximal response. After obtaining the maximal response to PHE (10^-5^M), the response curves to fenoldopam, a D~1~ receptor agonist \[[@B9],[@B10]\], were measured by a cumulative concentration-dependent protocol (10^-9^ to 10^-5^M). Response to every single concentration of fenoldopam was observed for 2 minutes. To test the vasorelaxant specific effects of D~1~ receptors, the arteries were incubated with the D~1~-like receptor antagonist SCH23390 (10^-7^M) for 30 minutes before fenoldopam treatment. In order to determine specificity of the vasodilatory effect of D~1~ receptor stimulation, we studied the vasodilation induced by sodium nitroprusside (SNP, 10^-10^ to 10^-4^M) in PHE-preconstricted mesenteric arteries.

Cell and sample preparation
---------------------------

Embryonic thoracic aortic smooth muscle cells from normotensive Berlin--Druckrey IX rats (A10, ATCC, Hercules, CA) were cultured at 37°C in 95% air/5% CO~2~ atmosphere in Dulbecco's Modified Eagle's Medium. A10 cells (80% confluence) and mesenteric arteries from Zucker rats were flash frozen by liquid nitrogen and homogenized in ice-cold lysis buffer (5 ml/gm tissue) (20 mM Tris-HCl, pH 7.4; 2 mM EDTA, pH 8.0; 2 mM EGTA; 100 mM NaCl; 10 μg/ml leupeptin; 10 μg/ml aprotinin; 2 mM phenylmethylsulfonyl fluoride; 1% NP-40), sonicated, kept on ice for 1 hr, and centrifuged at 16,000 g for 30 minutes. All samples were stored at -70°C until use.

Immunoblotting
--------------

After boiling the homogenates in sample buffer (35 mmol/L Tris-HCl, pH 6.8, 4% SDS, 9.3% dithiothreitol, 0.01% bromophenol blue, 30% glycerol) at 95°C for 5 min, 100 μg of protein were separated by SDS-PAGE (10% polyacrylamide), and then electroblotted onto nitrocellulose membranes (Bio-Rad). The blots were blocked overnight with 5% nonfat dry milk in phosphate buffered saline with Tween 20 (PBST) (0.05% Tween 20 in 10 mmol/l phosphate buffered (isotonic) saline) at 4°C with constant shaking, then incubated with polyclonal rabbit anti-rat D~1~ receptor antibodies (1:400 dilution; Millipore) overnight in the cold-room at 4°C. The membranes were then further incubated with infrared- labeled secondary antibodies (donkey anti-rabbit IRDye 800, Li-Cor Biosciences, Lincoln, NE) added to bind to the primary antibody at room temperature for 1 hr. The membranes were washed three times with PBST. The bound complex was detected using the Odyssey Infrared Imaging System (Li-Cor Biosciences). The images were analyzed using the Odyssey Application Software to obtain the integrated intensities.

Determination of basal D~1~ receptor phosphorylation by co-immunoprecipitation
------------------------------------------------------------------------------

Equal amounts of lysates (1.0 mg protein/ml supernatant from A10 cells or mesenteric artery) were incubated with polyclonal antiphosphoserine antibody (HKSP, New Territories, HK) (2.5 μg/ml) for 1 hr and protein-G agarose at 4°C for 12 hr. The immunoprecipitates were pelleted and washed four times with lysis buffer. The pellets were suspended in sample buffer, boiled for 10 min, and subjected to immunoblotting with polyclonal affinity-purified rabbit anti-rat D~1~ receptor antibody. In order to determine the specificity of the bands, normal rabbit IgG (negative control) and D~1~ receptor antibody (positive control) were used as the immunoprecipitants \[[@B23]\]. The bound complexes were detected using the Odyssey Infrared Imaging System (Li-Cor Biosciences). The images were analyzed using the Odyssey Application Software to obtain the integrated intensities.

Materials
---------

Fenoldopam, rosiglitazone maleate, STZ, mitogen-activated protein kinase (MAPK) inhibitor PD98059, Ach, SNP, PHE, and D~1~ receptor antagonist SCH23390 were obtained from Sigma-Aldrich (St. Louis, MO). Rabbit anti-rat D~1~ receptor polyclonal antibodies and rat insulin 96 well plate assay kit were obtained from Millipore Corporation (St Charles, MO); and anti-phosphoserine antibodies were obtained from Abcam Ltd (New Territories, Hong Kong, China).

Statistical analysis
--------------------

The data are expressed as mean ± SEM. Comparison within groups was made by repeated measures ANOVA (or paired *t-*test when only 2 groups were compared), and comparison among groups (or *t*-test when only 2 groups were compared) was made by factorial ANOVA with Holm-Sidak test. A value of *P \<* 0.05 was considered significant.

Results
=======

D~1~ receptor-mediated vasorelaxant effect is impaired in mesenteric arteries from obese Zucker rats
----------------------------------------------------------------------------------------------------

Consistent with previous reports \[[@B24]\], several variables, including body weight, and fasting plasma glucose and insulin concentrations and blood pressure, were higher in obese than lean Zucker rats (Table  [1](#T1){ref-type="table"}). Fenoldopam, the D~1~ receptor agonist, (10^-7^M to 10^-5^M) induced a concentration-dependent vasorelaxation in the third-order mesenteric arteries from lean Zucker rats (Figure  [1](#F1){ref-type="fig"}A). The absence of endothelium did not affect the fenoldopam-induced vasorelaxation, indicating that the fenoldopam-induced vasorelaxation was endothelium-independent (Figure  [1](#F1){ref-type="fig"}B). The vasorelaxant effect of fenoldopam was via a D~1~-like receptor because a D~1~-like receptor antagonist, SCH23390 (10^-7^M), blocked the fenoldopam-induced vasorelaxation (Figure  [1](#F1){ref-type="fig"}C), although SCH23390, by itself, was without any effect. The impaired vasorelaxant effect of fenoldopam was not a generalized phenomenon, because sodium nitroprusside (10^-10^ to 10^-4^M)-mediated vasodilation was not impaired in obese Zucker rats, consistent with previous reports \[[@B25],[@B26]\] (Figure  [1](#F1){ref-type="fig"}D).

![**Relaxation of phenylephrine (PHE)-preconstricted rat mesenteric arterial rings in response to fenoldopam and sodium nitroprusside (SNP).** Rat mesenteric arterial rings from obese and lean Zucker rats with (E+) **(A)** or without (E-) endothelium **(B)** were preconstricted with PHE (10^-5^M) and then treated with varying concentrations of fenoldopam (Fen, 10^-9^-10^-5^M) (\*P \< 0.01 vs. obese rats, n = 8). **(C):** D~1~-like receptor specificity of fenoldopam-induced vasorelaxation in rat mesenteric arterial rings. Rat mesenteric arterial rings from lean Zucker rats were preconstricted with PHE, and then incubated with fenoldopam (Fen, 10^-6^M) and/or SCH23390 (SCH, 10^-7^M) (\*P \< 0.01 vs. Fen, n = 6). **(D):** Rat mesenteric arterial rings from obese and lean Zucker rats with endothelium (E+) were preconstricted with PHE (10^-5^M) and then treated with varying concentrations of SNP (10^-10^-10^-4^M) (P = NS lean vs obese, n = 5).](1475-2840-13-50-1){#F1}

###### 

General and biochemical parameters of lean and obese Zucker rats (12-14 weeks old)

                             **Lean control**   **Obese control**    **Obese+ROG**    **Lean+HFD**    **Lean+STZ**
  ------------------------- ------------------ ------------------- ----------------- --------------- ---------------
  Body weight (g)              273.83±5.37        439.64±7.34\*       425.72±8.26     305.80±3.77\*   222.79±3.38\*
  Plasma glucose (mmol/L)       5.86±0.17          8.88±0.48\*       5.94±0.27^\#^      6.22±0.15       \>33.00\*
  Plasma insulin (ng/ml)        0.79±0.02          7.94±1.04\*       2.97±0.44^\#^     2.19±0.32\*     0.46±0.06\*
  Mean blood pressure          118.91±1.85        138.26±3.62\*     124.85±2.51^\#^    120.59±2.39    129.66±1.51\*

Values are means ±SE; n=6. \*P \< 0.05 vs. lean control rats; ^\#^P \< 0.05 vs. obese control rats.

Obese rats were treated with rosiglitazone (ROG): 10mg/kg/day for 6 weeks; Lean rats were treated with high fat diet (HFD) and streptozotocin (STZ) for 4 weeks.

To determine whether or not the arterial D~1~ receptor is involved in the pathogenesis of obesity-related hypertension, we studied the D~1~ receptor function in third-order mesenteric arteries from obese Zucker rats. We found that the fenoldopam-induced vasorelaxation was lost in obese Zucker rats in the presence (Figure  [1](#F1){ref-type="fig"}A) or absence (Figure  [1](#F1){ref-type="fig"}B) of the endothelium. The dysfunction of renal D~1~ receptor in hypertension \[[@B27]\] and obese Zucker rats \[[@B28],[@B29]\] has been reported to be caused by basal hyperphosphorylation of the renal D~1~ receptor. To determine whether or not this phenomenon also exists in third order mesenteric arteries of obese Zucker rats, D~1~ receptor expression and phosphorylation was studied by immunoblotting and immunoprecipitation. We found that D~1~ receptor expression was lower (Figure  [2](#F2){ref-type="fig"}A), while basal D~1~ receptor phosphorylation (Figure  [2](#F2){ref-type="fig"}B) in third order mesenteric arteries was higher in obese than lean Zucker rats.

![**D**~**1**~**receptor expression and phosphorylation in mesenteric arteries from lean and obese Zucker rats. (A):** D~1~ receptor expression was determined by immunoblotting. **(B):** Serine-phosphorylated D~1~ receptor in rat mesenteric arteries was determined by co-immunoprecipitation and immunoblotting. Normal rabbit IgG (negative control) or D~1~ receptor antibody (positive control) was used as the immunoprecipitant. D~1~ receptor serine phosphorylation was normalized by D~1~ receptor protein. (\*P \< 0.05 vs. lean rats, n = 6).](1475-2840-13-50-2){#F2}

Roles of hyperinsulinemia and hyperglycemia in the D~1~ receptor vascular dysfunction in obese Zucker rats
----------------------------------------------------------------------------------------------------------

The pathogenesis of obesity is complex. To determine whether or not high plasma levels of glucose and insulin are involved in the obesity-related hypertension, the obese Zucker rats were treated with the insulin sensitizer \[[@B30]\], rosiglitazone (10 mg/kg oral, daily). We found that rosiglitazone restored the impaired fenoldopam-mediated vasorelaxation in obese Zucker rats (Figure  [3](#F3){ref-type="fig"}A), increased the decreased D~1~ receptor expression (Figure  [3](#F3){ref-type="fig"}B), and decreased the increased phosphorylation (Figure  [3](#F3){ref-type="fig"}C) of D~1~ receptor in mesenteric arteries from obese Zucker rats consistent with those reported in the kidney \[[@B28]\].

![**Effect of rosiglitazone on D**~**1**~**receptor expression and function in mesenteric arteries from obese Zucker rats.** The mesenteric arteries from obese Zucker rats, treated with rosiglitazone (ROG) or vehicle, were incubated with varying concentrations of fenoldopam (10^-9^-10^-5^M). The vasorelaxation with fenoldopam is shown in **3A** (\*P \< 0.05, vs. obese rats, n = 8 repeated measures ANOVA, Holm-Sidak test) while D~1~ receptor expression or phosphorylation in mesenteric arteries, determined by immunoblotting or co-immunoprecipitation, is shown in **3B and 3C,** respectively. D~1~ receptor serine phosphorylation was normalized by D~1~ receptor protein. (\*P \< 0.05, vs. obese rats, n = 6),](1475-2840-13-50-3){#F3}

Consistent with other reports \[[@B28],[@B30]\], our current study found that rosiglitazone reduced plasma insulin and glucose levels and blood pressure (Table  [1](#T1){ref-type="table"}). Therefore, it was difficult to determine whether hyperinsulinemia, hyperglycemia, or both led to the dysfunction of the arterial D~1~ receptor. To overcome this dilemma, we used the hyperinsulinemic and hyperglycemic lean Zucker rat models. Lean Zucker rats fattened by a high-fat diet for one month developed hyperinsulinemia but had normal blood pressure, similar to other reports \[[@B31],[@B32]\]. To establish a hyperglycemia model, lean Zucker rats were intraperitoneally injected with a single dose of STZ (65 mg/kg) \[[@B33]\]; the STZ-treated lean Zucker rats would be expected to develop slightly high blood pressure and hyperglycemia but with low plasma insulin levels (Table  [1](#T1){ref-type="table"}), as described by others \[[@B34]\]. We found that both hyperinsulinemic (Figure  [4](#F4){ref-type="fig"}A) and hyperglycemic (Figure  [4](#F4){ref-type="fig"}B) lean Zucker rats had impaired D~1~ receptor-mediated vasorelaxation, accompanied by decreased D~1~ receptor expression (Figure  [4](#F4){ref-type="fig"}C) and increased D~1~ receptor phosphorylation (Figure  [4](#F4){ref-type="fig"}D), but the dysfunction of the D~1~ receptor was greater in the hyperinsulinemia than hyperglycemia model, indicating that insulin plays a more important role than hyperglycemia in the impairment of arterial D~1~ receptor-mediated relaxation (Figures  [4](#F4){ref-type="fig"}A-D).

![**D**~**1**~**receptor expression and function in lean Zucker rats with hyperinsulinemia or hyperglycemia.** Lean Zucker rats were fed high-fat diet (HFD) to induce hyperinsulinemia or intraperitoneally injected with streptomycin (STZ) to induce hyperglycemia. The mesenteric arteries preconstricted with PHE from those rats were treated with varying concentrations of fenoldopam (Fen, 10^-9^-10^-5^M) **(A and B)** (\*P \< 0.05, vs. lean Zucker rats, n = 8). D~1~ receptor expression was determined by immunoblotting **(C)** and D~1~ receptor phosphorylation **(D)** was determined by co-immunoprecipitation and immunobloting. D~1~ receptor serine phosphorylation was normalized by D~1~ receptor protein (\*P \< 0.05, vs. obese rats, n = 6).](1475-2840-13-50-4){#F4}

Effect of insulin and glucose on D~1~ receptor expression and phosphorylation in A10 cells
------------------------------------------------------------------------------------------

To further confirm the *in vivo* results, the effects of high insulin and high glucose concentrations on D~1~ receptor expression and phosphorylation were studied in A10 cells, a rat thoracic aorta-derived smooth muscle cell line. Treatment with insulin (Figures  [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B) or high glucose (Figures  [5](#F5){ref-type="fig"}C and [5](#F5){ref-type="fig"}D) decreased D~1~ receptor expression and increased D~1~ receptor phosphorylation. In the presence of a MAP kinase inhibitor, PD98059 (10^-6^ M), the effects of insulin on D~1~ receptor expression and phosphorylation were blocked, indicating that MAP kinase is involved in the signaling pathway (Figures  [6](#F6){ref-type="fig"}A and [6](#F6){ref-type="fig"}B).

![**Effect of insulin and glucose on D**~**1**~**receptor expression and phosphorylation in A10 cells.** A10 cells were treated with varying concentrations of insulin **(A and B)** or glucose **(C and D)** for 24 hrs. D~1~ receptor expression was determined by immunoblotting. A10 cells were treated with insulin (10^-7^M) and glucose (35 mM) for 24 hrs. D~1~ receptor expression and phosphorylation were determined by co-immunoprecipitation or immunoblotting. D~1~ receptor serine phosphorylation was normalized by D~1~ receptor protein (\*P \< 0.05, vs. control, n = 5).](1475-2840-13-50-5){#F5}

![**Role of MAP kinase in the regulation by insulin of D**~**1**~**receptor expression and phosphorylation in A10 cells.** A10 cells were treated with insulin (10^-7^M) in the presence or absence of the MAP kinase inhibitor PD98059 (10^-6^M) for 24 hrs. D~1~ receptor expression **(A)** or phosphorylation **(B)** was determined by immunoblotting or co-immunoprecipitation. D~1~ receptor serine phosphorylation was normalized by D~1~ receptor protein. (\*P \< 0.01, vs. control; ^\#^P \< 0.05, vs. insulin, n = 5).](1475-2840-13-50-6){#F6}

Discussion
==========

Role of hyperinsulinemia in obesity-related hypertension
--------------------------------------------------------

Obesity is a well-known risk factor for hypertension \[[@B15],[@B35]\]. Indeed, risk estimates according to the Framingham study show that roughly 80% of essential hypertension in men and 65% in women can be directly attributed to obesity \[[@B36]\]. It is accepted that insulin resistance is epidemiologically linked with hypertension \[[@B37],[@B38]\]. The compensatory hyperinsulinemia that occurs with insulin resistance increases renal sodium reabsorption and sympathetic activity and leads to elevated arterial pressure \[[@B39]\]. Insulin resistance and compensatory hyperinsulinemia impair the production of nitric oxide and favor the production of vasoconstrictors \[[@B40]-[@B42]\]. Our current study found hyperinsulinemia, hyperglycemia, and elevated blood pressure in obese Zucker rats that were reduced by rosiglitazone treatment similar to previous reports \[[@B43],[@B44]\]. We also found that lean Zucker rats fed a high fat diet had hyperinsulinemia and STZ-treated lean Zucker rats were hyperglycemic and hypoinsulinemic, similar to other reports \[[@B31],[@B45]\].

Impairment of D~1~ receptor-mediated vasodilation is involved in obesity-related hypertension
---------------------------------------------------------------------------------------------

Dopamine has been reported as an important modulator of sodium balance, renal and adrenal function, and blood pressure and is relevant to the pathogenesis and/or maintenance of hypertension. In humans with essential hypertension and rodents with genetic hypertension (SHRs and Dahl salt-sensitive rats), D~1~-like receptor agonist-mediated natriuretic and diuretic responses are impaired \[[@B46],[@B47]\]. The ability of D~1~-like receptors to stimulate adenylyl cyclase activity in renal arteries is also impaired in SHRs \[[@B48]\] and we have also reported an impaired ability of D~1~ receptors to dilate the mesenteric arteries of SHRs \[[@B49]\]. Other studies have shown that the D~1~ receptor is hyperphosphorylated and uncoupled from G protein subunits, leading to the D~1~ receptor dysfunction in SHRs, which precedes the onset of hypertension and co-segregates with the hypertensive phenotype \[[@B10],[@B50]\]. Thus, D~1~ receptor dysfunction is a primary defect in the hypertension of SHRs. Lokhandwala *et al* have found that obese Zucker rats have defective renal D~1~ receptor function associated with a decrease in D~1~ receptor expression and ability to inhibit Na, K-ATPase and Na,H-exchanger activities in renal proximal tubules \[[@B13],[@B28],[@B30]\]. These authors suggested that the renal dopaminergic dysfunction in obese Zucker rats is acquired and not inherited \[[@B14]\] and could be ameliorated by inhibition of reactive oxygen species production by tempol and insulin sensitization by rosiglitazone \[[@B28],[@B29]\]. Because increased peripheral vascular resistance and altered vascular reactivity are distinctive features of essential hypertension \[[@B16]\], we tested the hypothesis that the hypertension of obese Zucker rats may be caused by an impairment of D~1~ receptor-mediated vasodilation. This was indeed the case as the D~1~ receptor-mediated vasorelaxation was impaired in obese Zucker rats. This dysfunction of the D~1~ receptor could be ascribed to the decreased D~1~ receptor expression and increased D~1~ receptor phosphorylation because the rosiglitazone-mediated amelioration of the impaired D~1~ receptor relaxant effect was associated with an increase in D~1~ receptor expression and a decrease in D~1~ receptor phosphorylation. Rosiglitazone, a PPARγ agonist, has many effects on the cardiovascular system independent of its insulin sensitizing effects, including anti-inflammation and direct stimulation of NO production \[[@B51]\]. Whether or not such mechanisms were involved in the rosiglitazone-mediated improvement of the vasodilatory effect of the D~1~ receptor in the current report needs to be determined in a future study.

Role of hyperinsulinemia or hyperglycemia in the dysfunction of arterial D~1~ receptor in obese Zucker rats
-----------------------------------------------------------------------------------------------------------

Obese Zucker rats have increased plasma insulin and fasting glucose levels \[[@B24],[@B52],[@B53]\]. As stated above, treatment of obese Zucker rats with rosiglitazone reduced plasma insulin and glucose levels and improved the vasorelaxant effect of fenoldopam that was associated with an increase in the vascular expression of D~1~ receptor and a decrease in vascular serine-phosphorylated D~1~ receptor. Thus, hyperinsulinemia and hyperglycemia may be involved in the defective fenoldopam-mediated relaxation in small mesenteric arteries isolated from obese Zucker rats. In order to identify the mechanisms that caused the impaired D~1~ receptor vasodilatory function in obese Zucker rats, we used two rat models: high fat diet-induced hyperinsulinemia and STZ-induced type 1 diabetes in lean Zucker rats. The former rat model is characterized by insulin resistance and hyperinsulinemia \[[@B31],[@B32]\] while the latter rat model is characterized by hyperglycemia and low plasma insulin levels \[[@B33],[@B34]\]. After the establishment of hyperinsulinemia or hyperglycemia, mesenteric arteries had an impaired fenoldopam-mediated vasorelaxation that was more evident in the high fat diet-fed hyperinsulinemic rats than STZ-induced type I diabetic rats. Therefore, both hyperinsulinemia and hyperglycemia are involved in the dysfunction of the arterial D~1~ receptor, but hyperinsulinemia plays a more important role than hyperglycemia in this phenomenon.

The ability of increased insulin and glucose concentrations to decrease D~1~ receptor expression and increase D~1~ receptor phosphorylation *in vivo* was confirmed *in vitro* in A10 cells. Treatment of A10 cells with insulin decreased D~1~ receptor expression and increased D~1~ receptor phosphorylation, consistent with the findings in renal proximal tubule cells \[[@B54],[@B55]\]. Mitogen-activated protein kinase (MAPK) is activated in cardiovascular diseases such as diabetes and hypertension \[[@B56],[@B57]\]. The up-regulation of MAPK reduces renal D~1~ receptor affinity and G-protein coupling in obese rats \[[@B58]\]. The current studies also showed that blockade of MAPK reversed both the decreased D~1~ receptor expression and increased D~1~ receptor phosphorylation caused by high insulin in A10 cells.

Limitations
-----------

Besides of the role of hyperinsulinemia and hyperglycemia in the D~1~-receptor mediated arterial dysfunction, adiponectin, as an important adipose tissue-derived factor, might have some effect on dopamine function. For example, monosodium glutamate induces obesity in rodents markedly decreases adiponectin levels \[[@B59]\] and compromises dopaminergic systems \[[@B60]\]. Moreover, dopamine stimulates adiponectin release \[[@B61]\], and antidiabetic treatment in Zucker diabetic fatty rats inhibits the development of hypo-adiponectinemia in mesenteric resistance arteries, but is not able to improve adiponectin induced vasodilation \[[@B62]\]. Whether or not the plasma adiponectin would affect arterial dopamine receptor function needs to be determined in the future study.

Conclusions
===========

In summary, this study shows that both hyperinsulinemia and hyperglycemia impair vascular D~1~ receptor function that is associated with decreased D~1~ receptor expression and increased D~1~ receptor phosphorylation. Besides, hyperinsulinemia plays a more important role than hyperglycemia in the dysfunction of the arterial D~1~ receptor in obese Zucker rats. Impaired D~1~ receptor-mediated vasorelaxation is involved in the pathogenesis of obesity-related hypertension.
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